Diamminedichloroplatinum , cis

Amat, L. and Carbo-Dorca, R. (1999) Fitted electronic density functions from H to Rn for use in quantum similarity measures cis-diamminedichloroplatinum(II) complex as an application example. [Pg.291]

Nishio, K., Sugimoto, Y., Fujiwara, Y., Ohmoii, T Moiikage, T, Takeda, Y., and Saijo, N., 1992, Phospholipase C-mediated hydrolysis of phosphotidylcholine is activated by cis-diamminedichloroplatinum (II)- J- Clin. Invest. 89 1622-1628. [Pg.282]

The most widely used drug in this category is cisplatin. Therfeore, we have summarized below its action at the chromatin level. The anti-tumour drug cis-diamminedichloroplatinum(II) (cisplatin) is employed for the treatment of ovarian and testicular carcinomas, as well as solid tumours (Loehrer and Einhorn, 1984 Zamble and Lippard 1995). [Pg.168]

Husain A, Yan XJ, Rosales N, Aghajanian C, Schwartz GK, Sprigs DR (1997) UCN-01 in Ovary Cancer Cells Effective as a Single Agent and in Combination with cis-Diamminedichloroplatinum(Il)Independent of pS3 Status. Clin Cancer Res 3 2089-2097... [Pg.75]

Ohmori T, Arteaga C]L (1998) Protein kinase C epsilon translocation and phosphorylation by cis-diamminedichloroplatinum(II) (CDDP) potential role in CDDP-mediated cytotoxicity. Cell Growth Differ 9 345-353 Ojeda F, Guarda MI, Maldonado C, Folch H, Diehl H (1992) Role of protein kinase-C in thymocyte apoptosis induced by irradiation. Int J Radiat Biol 61 663-667 Oka M, Ogita K, Ando H, Horikawa T, Hayashibe K, Saito N, Kikkawa U, Ichihashi M (1996) Deletion of specific protein tdnase C subspecies in human melanoma cells. J Cell Physiol 167 406-412... [Pg.85]

Perez C, Leng M, Malinge JM. Rearrangement of interstrand crosslinks into intrastrand crosslinks in cis-diamminedichloroplatinum(II)-modified DNA. Nucleic Acids Res 1997 25 896-903. [Pg.57]

Teicher BA, Holden S A, Herman TS, et al. Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II). Int J Cancer 1991 47 252-260. [Pg.58]

Katabami M, Fijita H, Haneda H, et al. Reduced drug accumulation in a newly established human lung squamous-carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Biochem Pharmacol 1992 44 394-397. [Pg.58]

Andrews PA, Velury S, Mann SC, Howell SB. Cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 1988 48 68-73. [Pg.58]

Scanlon KJ, Safirsten RL, Thies H, Gross RB, Waxman S, Guttenplan JB. Inhibition of amino acid transport by cis-diamminedichloroplatinum(II) derivatives in L1210 murine leukemia cells. Cancer Res 1983 43 4211 1215. [Pg.58]

Soloway MS, Morris CR, Sudderth B. Radiation therapy and cis-diamminedichloroplatinum(II) in transplantable and primary murine bladder cancer. Int J Radiat Oncol Biol Phys 1979 5 1355-1360. [Pg.59]

DewitL. Combined treatment ofradiation and cis-diamminedichloroplatinum (II) A review of experimental and clinical data. Int J Radiat Oncol Biol Phys 1987 13 403-426. [Pg.59]

Bartelink H, Kallmann RF, RapacchiettaD, Hart A AM. Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of cis-diamminedichloroplatinum(II) and irradiation. Radiotherap Oncol 1986 6 61-74. [Pg.59]

Stewart DJ, Leavens M, Maor M, et al. Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 1982 42 2474-2479. [Pg.60]

Fichtinger-Schepman AMJ, Dijt FJ, De Jong WH, van Oosterom AR, Berends F. In vivo cis-diamminedichloroplatinum(II)-DNA adduct formation and removal as measured with immunochemical techniques. In (Nicolini M, ed), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 1988 Martinus Nijhoff Publishing Boston, pp. 32-46. [Pg.60]

Boscia RE, Korbut T, Holden SA, Ara G, Teicher BA. Interaction of topoisomerase I inhibitors with radiation in cis- diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo. Int J Cancer 1993 53(1 ) 118-123. [Pg.103]

Schwartz JL, Rotmensch J, Beckett MA, et al. X-ray and cis-diamminedichloroplatinum (II) crossresistance in human tumor cell lines. Cancer Res 1988 48 5133-5135. [Pg.211]

Kyriazis AP, Yagoda A, Kereiakes JG. Experimental studies on the radiation-modifying effect of cis-diamminedichloroplatinum II (DDP) in human bladder transitional cell carcinomas grown in nude mice. Cancer 1983 52 452-457. [Pg.301]

Fan Z, Baselga J, Masui H, et al. Antitumor effect of anti-epidermal growth factorreceptormonoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993 53 4637 1642. [Pg.335]

Husain A, He G, Venkatraman ES et al. BRCAl up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum (II). Cancer Res I998 58 I I20-II23. [Pg.245]

Over the past 20 years, cis-diamminedichloroplatinum(II), known for more than 145 years, has emerged as the classic compound in the context of antitumor drug therapy. Because it is generally accepted that binding of the compound to DNA is a major requirement for its biological activity, scientists have focused their attention especially on platinum-DNA interactions. In the present review, the latest results... [Pg.175]

Miller CA, Cohen MD, Costa M. 1991. Complexing of actin and other nuclear proteins to DNA by cis-diamminedichloroplatinum(II) and chromium compounds. Carcinogenesis 12(2) 269-276. [Pg.445]

Jennerwein M, Andrews PA (1995) Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II). Drug Metab Dispos 23 178-184... [Pg.51]

Greco WR, Park HS, Rustum YM. 1990. An application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-b-D-arabinosefuranosylcytosine. Cancer Res 50 5318-5327. [Pg.241]

Kinoshita, M., Yoshimura, N., Ogata, H., Tsujino, D., Takahashi, T., Takahashi, S., Wada, Y., Someya, K., Ohno, T., Masuharra, K., Tanaka, Y. High-performance liquid-chromato-graphic analysis of unchanged cis-diamminedichloroplatinum (cisplatin) in plasma and urine with post-column derivatization. J. Chromatogr. B 529, 462-467 (1990)... [Pg.391]

SYNS CACP CDDP CISPLATINO (SPANISH) CISPLATYL CPDC CPDD DDP ds-DDP cis-DIAMMINEDICHLOROPLATINUM cis-DICHLORO-DIAMMINE PLATINUM(II) NCI-C55776 NEOPLA-TIN NSC-119875 PEYRONE S CHLORIDE PLATIBLASTIN cis-PLATIN PLATINEX ... [Pg.1135]

Andrews PA, Mann SC, Huynh HH, Albright KD. Role of the sodium,potassium-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells. Cancer Res. 1991 51 3677-3681. [Pg.2177]

The present drug of choice for this purpose is cis-platin [cis-diamminedichloroplatinum (II)], or its analog carboplatin. As will be discussed in Chapter 30, early compartmental models predicted a substantial pharmacokinetic advantage of intraperitoneal over intravenous delivery (8). A later Phase III trial (7) confirmed that a comparative survival advantage... [Pg.111]

Los G, Mutsaers PHA, van der Vijgh WJF, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy A comparison with systemic chemotherapy. Cancer Res 1989 49 3380-4. [Pg.127]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...